1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cantargia AB (publ)

Cantargia AB (publ)

CANTA.ST
Cantargia AB (publ)SE flagStockholm Stock Exchange
2.02
SEK
-0.09
- -
502.69MMarket Cap
Cantargia AB (publ)
CANTA.ST
(Stockholm Stock Exchange)

Recent

price

2.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.27
1.28
Revenue per Share
-0.2
-0.2
-0.47
-0.49
-1
-2.27
-1.55
-1.15
-1.3
-1.61
-3.66
-2.9
-1.65
-0.88
0.59
0.65
Basic EPS, GAAP
-0.17
-0.22
-0.54
0.36
-1.86
-2.02
-1.05
-1.32
-1.38
-1.54
-3.46
-2.86
-1.69
-0.89
0.6
0.63
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.24
-0.45
-0.91
-1.4
-2.38
-4.2
-3.75
-2.96
-4.05
-4.77
-8.7
-9.63
-8.88
-9.04
-6.08
-6.21
Book Value per Share
0.07
0.13
0.08
0.1
1.38
1.43
6.32
1.95
1.66
8.24
5.25
3
0.97
0.61
1.06
0.93
Tangible Book Value per Share
17
17
17
17
17
21
39
80
85
107
100
128
170
184
249
249
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
317
317
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
48.75
51.15
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
3
4
3
3
3
3
Depreciation Expense
-3
-3
-8
-8
-17
-47
-60
-91
-111
-173
-367
-372
-280
-162
147
161
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
46.41
50.73
Profit Margin (%)
1
2
1
1
22
27
243
152
135
882
524
377
159
110
263
232
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
2
3
3
4
24
30
246
155
142
892
533
390
169
116
266
234
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-9.53
-10.95
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
249
249
249
Market Capitalization
595
1,039
1,017

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
355
293
265
Cash, Cash Equivalents & STI
339
282
258
Accounts Receivable, Net
- -
5
1
Inventories
- -
- -
- -
Total Current Liabilities
61
30
33
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
120.12%
-5.26%
128.61%
Free Cash Flow
9.61%
-28.33%
-191.96%
Net Income, GAAP
18.75%
-28.94%
-190.92%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
309
8
317
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
-0.24
-0.23
-0.21
-0.88
2025
-0.19
-0.16
1.07
-0.13
0.59
2026
-0.13
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
Humanigen, Inc. (HGENQ)
BioSyntech, Inc. (BSYI)
BioMarin Pharmaceutical Inc. (BM8.DE)
Oncternal Therapeutics, Inc. (ONCT)
Philogen S.p.A. (PHIL.MI)
Business
Cantargia AB (publ) (CANTA.ST) is a biotechnology company focused on the research, development, and commercialization of antibody-based therapies for cancer and inflammatory diseases. The company develops proprietary antibody therapeutics targeting the IL1RAP protein, including its lead candidate CAN10, an antibody in clinical development for autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), non-infectious uveitis, and acute respiratory distress syndrome (ARDS); and CAN04 (nadunolimab), a first-in-class antibody for cancer indications including non-small cell lung cancer (NSCLC), pancreatic cancer, and triple-negative breast cancer, which is being evaluated in combination with chemotherapy or immune checkpoint inhibitors. Cantargia operates primarily in the biopharmaceutical sector, targeting patients with high unmet medical needs in oncology and autoimmunity, with clinical-stage programs conducted through partnerships and trials across Europe and the United States. Founded in 2007 and headquartered in Lund, Sweden, the company conducts its research and development activities from facilities in Lund and has expanded its geographic footprint through international clinical collaborations. In recent developments within the last two years, Cantargia reported positive interim data from the Phase IIb CANergy trial of CAN04 in combination with chemotherapy for pancreatic cancer in 2024, strengthening its oncology pipeline; entered a strategic manufacturing partnership with AGC Biologics for CAN10 production to support upcoming clinical trials announced in early 2025; secured additional funding through a rights issue in late 2024 raising approximately SEK 200 million to advance both CAN04 and CAN10 programs; and initiated patient dosing in the Phase I trial of CAN10 for autoimmune uveitis in mid-2025, marking a significant expansion into inflammatory indications.